AcelRx Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. AcelRx Pharmaceuticals shares (ACRX) are listed on the NASDAQ and all prices are listed in US Dollars. AcelRx Pharmaceuticals employs 19 staff and has a trailing 12-month revenue of around $370,000.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.72 - $1.61 |
|---|---|
| 50-day moving average | $0.76 |
| 200-day moving average | $0.84 |
| Wall St. target price | $4.63 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.75 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
| Revenue TTM | $370,000 |
|---|---|
| Gross profit TTM | $-3,341,000 |
| Return on assets TTM | -32.22% |
| Return on equity TTM | -51.12% |
| Profit margin | 0% |
| Book value | $1.08 |
| Market Capitalization | $14.6 million |
TTM: trailing 12 months
We're not expecting AcelRx Pharmaceuticals to pay a dividend over the next 12 months.
AcelRx Pharmaceuticals's shares were split on a 1:20 basis on 25 October 2022 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AcelRx Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for AcelRx Pharmaceuticals shares which in turn could have impacted AcelRx Pharmaceuticals's share price.
Over the last 12 months, AcelRx Pharmaceuticals's shares have ranged in value from as little as $0.72 up to $1.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AcelRx Pharmaceuticals's is 0.517. This would suggest that AcelRx Pharmaceuticals's shares are less volatile than average (for this exchange).
AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Access remote advice, planning and portfolio management from this established financial services company.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2025.
A deep dive into the highlights and limitations of Robinhood.
This account boasts commission-free trades and no minimums but has a low cash sweep rate.